Full Text Journal Articles about
Glioblastoma Multiforme

Advertisement

Find full text journal articles






Silencing hsa_circ_PVT1 (circPVT1) suppresses the growth and metastasis of glioblastoma multiforme cells by up-regulation of miR-199a-5p.

Guonan Chi, Fuwei Yang, Donghui Xu, Weiming Liu,

Background: Glioblastoma multiforme (GBM) is one of the most prevailing primary brain tumours among adults and most aggressive cancers. Despite multiple developments in medical and surgical treatments, GBM is still a deadly disease with a high mortality rate. Here, this study was performed to investigate the function of circPVT1 on ... Read more >>

Artif Cells Nanomed Biotechnol (Artificial cells, nanomedicine, and biotechnology)
[2020, 48(1):188-196]

Cited: 0 times

View full text PDF listing >>



Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells.

Alisha T Poole, Christopher A Sitko, Caitlin Le, Christian C Naus, Bryan M Hill, Eric A C Bushnell, Vincent C Chen,

Glioblastoma multiforme (GBM) is the deadliest and the most common primary malignant brain tumour. The median survival for patients with GBM is around one year due to the nature of glioma cells to diffusely invade that make the complete surgical resection of tumours difficult. Based upon the connexin43 (Cx43) model ... Read more >>

J Enzyme Inhib Med Chem (Journal of enzyme inhibition and medicinal chemistry)
[2020, 35(1):672-681]

Cited: 0 times

View full text PDF listing >>



Advertisement

c(RGDyk)-modified nanoparticles encapsulating quantum dots as a stable fluorescence probe for imaging-guided surgical resection of glioma under the auxiliary UTMD.

Qi-Long Wu, He-Lin Xu, Cui Xiong, Qing-Hua Lan, Ming-Ling Fang, Jin-Hua Cai, Hui Li, Shu-Ting Zhu, Jing-Hong Xu, Fang-Yi Tao, Cui-Tao Lu, Ying-Zheng Zhao, Bin Chen,

Surgical resection remains the preferred approach for some patients with glioblastoma (GBM), and eradication of the residual tumour niche after surgical resection is very helpful for prolonging patient survival. However, complete surgical resection of invasive GBM is difficult because of its ambiguous boundary. Herein, a novel targeting material, c(RGDyk)-poloxamer-188, was ... Read more >>

Artif Cells Nanomed Biotechnol (Artificial cells, nanomedicine, and biotechnology)
[2020, 48(1):143-158]

Cited: 0 times

View full text PDF listing >>



Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS.

Liliana E Lucca, Benjamin A Lerner, Calvin Park, Danielle DeBartolo, Brian Harnett, Varun P Kumar, Gerald Ponath, Khadir Raddassi, Anita Huttner, David A Hafler, David Pitt,

OBJECTIVE:To identify coinhibitory immune pathways important in the brain, we hypothesized that comparison of T cells in lesions from patients with MS with tumor-infiltrating T cells (TILs) from patients with glioblastoma multiforme may reveal novel targets for immunotherapy. METHODS:We collected fresh surgical resections and matched blood from patients with glioblastoma, ... Read more >>

Neurol Neuroimmunol Neuroinflamm (Neurology(R) neuroimmunology & neuroinflammation)
[2020, 7(3):]

Cited: 0 times

View full text PDF listing >>



Glioblastoma evolving within 10 days following unremarkable computer tomography of the brain: A case report.

Nils Schröter, Niklas Lützen, Soroush Doostkam, Benjamin Berger,

Glioblastoma multiforme might develop radiologically within a few days following unremarkable CT scan of the brain. Glioblastoma multiforme is the most frequent primary brain tumor. Initial presentations are diverse, including headache, seizures and transient or persistent neurological deficits. Cerebral imaging followed by histological examination of a tissue specimen is the ... Read more >>

Int. J. Neurosci. (The International journal of neuroscience)
[2020, :1-5]

Cited: 0 times

View full text PDF listing >>



Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma.

Sarah Meneceur, Annett Linge, Matthias Meinhardt, Sandra Hering, Steffen Löck, Rebecca Bütof, Dietmar Krex, Gabriele Schackert, Achim Temme, Michael Baumann, Mechthild Krause, Cläre von Neubeck,

Glioblastoma is an aggressive brain tumour with a patient median survival of approximately 14 months. The development of innovative treatment strategies to increase the life span and quality of life of patients is hence essential. This requires the use of appropriate glioblastoma models for preclinical testing, which faithfully reflect human ... Read more >>

Cancers (Basel) (Cancers)
[2020, 12(4):]

Cited: 0 times

View full text PDF listing >>



A review of glioblastoma immunotherapy.

Ravi Medikonda, Gavin Dunn, Maryam Rahman, Peter Fecci, Michael Lim,

INTRODUCTION:Glioblastoma is a very aggressive cancer with dismal prognosis despite standard of care including surgical resection, radiation therapy, and chemotherapy. There is interest in applying immunotherapy to glioblastoma as this modality has demonstrated remarkable improvements in the management of several solid tumors including melanoma, renal cell carcinoma, and non-small cell ... Read more >>

J. Neurooncol. (Journal of neuro-oncology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Inhibition of Cathepsin D (CTSD) enhances radiosensitivity of glioblastoma cells by attenuating autophagy.

Wang Zheng, Qianping Chen, Chen Wang, Dan Yao, Lin Zhu, Yan Pan, Jianghong Zhang, Yang Bai, Chunlin Shao,

Postoperative radiotherapy combined with chemotherapy is a commonly used treatment for glioblastoma (GBM) but radiotherapy often fails to achieve the expected results mainly due to tumor radioresistance. In this study, we established a radioresistant subline from human glioma cell line U251 and found that Cathepsin D (CTSD), a gene closely ... Read more >>

Mol. Carcinog. (Molecular carcinogenesis)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.

Chong Hyun Suh, Ho Sung Kim, Seung Chai Jung, Choong Gon Choi, Sang Joon Kim, Kyung Won Kim,

OBJECTIVE:We aimed to determine the optimized image-based surrogate endpoints (IBSEs) in targeted therapies for glioblastoma through a systematic review and meta-analysis of phase III randomized controlled trials (RCTs). MATERIALS AND METHODS:A systematic search of OVID-MEDLINE and EMBASE for phase III RCTs on glioblastoma was performed in December 2017. Data on ... Read more >>

Korean J Radiol (Korean journal of radiology)
[2020, 21(4):471-482]

Cited: 0 times

View full text PDF listing >>



Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: nanomedicine approaches to improve their efficacy.

Juan Aparicio-Blanco, Lorena Sanz-Arriazu, Ricardo Lorenzoni, María J Blanco-Prieto,

Even though substantial advances in understanding glioma pathogenesis have prompted a more rational design of potential therapeutic strategies, glioblastoma multiforme remains an incurable disease with the lowest median overall survival among all malignant brain tumours. Therefore, there is a dire need to find novel drug delivery strategies to improve the ... Read more >>

Int J Pharm (International journal of pharmaceutics)
[2020, :119283]

Cited: 0 times

View full text PDF listing >>



High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11).

Itsuki Yamaguchi, Shige H Yoshimura, Hironori Katoh,

The the cystine/glutamate transporter system xc- consists of the light-chain subunit xCT (SLC7A11) and the heavy-chain subunit CD98 (4F2hc or SLC3A2) and exchanges extracellular cystine for intracellular glutamate at the plasma membrane. The imported cystine is reduced to cysteine and used for synthesis of glutathione, which is one of the ... Read more >>

J. Biol. Chem. (The Journal of biological chemistry)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Major Contribution of Caspase-9 to Honokiol-Induced Apoptotic Insults to Human Drug-Resistant Glioblastoma Cells.

Gong-Jhe Wu, Sun-Ta Yang, Ruei-Ming Chen,

Temozolomide (TMZ)-induced chemoresistance to human glioblastomas is a critical challenge now. Our previous studies showed that honokiol, a major bioactive constituent of Magnolia officinalis (Houpo), can kill human glioblastoma cells and suppresses glioblastoma growth. This study was further aimed to evaluate the effects of honokiol on human drug-resistant glioblastoma cells ... Read more >>

Molecules (Molecules (Basel, Switzerland))
[2020, 25(6):]

Cited: 0 times

View full text PDF listing >>



Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma.

Elizabeth G Graham-Gurysh, Kathryn Moore, Allison N Schorzman, Taek Lee, William C Zamboni, Shawn Hingtgen, Eric M Bachelder, Kristy M Ainslie,

Current interstitial therapies for glioblastoma can overcome the blood-brain barrier, but fail to optimally release therapy at a rate which stalls cancer reoccurrence. To address this lapse, acetalated dextran (Ace-DEX) nanofibrous scaffolds were used for their unique degradation rates that translate to a broad range of drug release kinetics. A ... Read more >>

ACS Appl Mater Interfaces (ACS applied materials & interfaces)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Predictive markers of immune response in glioblastoma: hopes and facts.

Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Stefania Bartolini, Alba Ariela Brandes,

Immune-checkpoint inhibitors (ICI) represent a concrete hope for patients with advanced solid tumors. Indeed, patients responding to these agents may experience a long-lasting response. Recently, results of interventional clinical trials investigated the role of ICIs in patients with glioblastoma. Results of these studies suggested that only a small percentage of ... Read more >>

Future Oncol (Future oncology (London, England))
[2020, :]

Cited: 0 times

View full text PDF listing >>



Profiling anti-apoptotic protein BCL-xL expression in U-87 MG glioblastoma cells and patient-derived tumorspheres

Fanfone, Gabut, Ichim,

Abstract Glioblastoma is one of the cancers with the worst prognosis, despite huge efforts to understand its unusual heterogeneity and aggressiveness. These are mainly attributable to glioblastoma stem cells, which are also responsible for the frequent tumour recurrence following surgery or chemo/radiotherapy. We report here that tumorspheres derived from the ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Small molecule tyrosine kinase inhibitors in glioblastoma.

Gayoung Kim, Young Tag Ko,

Glioblastoma (GBM) is the most common malignant primary brain tumor, with poor survival despite treatment with surgery, radiotherapy, and chemotherapy with temozolomide. Little progress has been made over the last two decades, and there remain unmet medical needs. Approximately 45% of patients with GBM carry EGFR mutations, and 13% of ... Read more >>

Arch. Pharm. Res. (Archives of pharmacal research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.

Yuji Matsumoto, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Yoshihiro Otani, Atsushi Fujimura, Kentaro Fujii, Yusuke Tomita, Yasuhiko Hattori, Atsuhito Uneda, Nobushige Tsuboi, Keisuke Kaneda, Keigo Makino, Isao Date,

Glioblastoma (GBM) is characterized by extensive tumor cell invasion, angiogenesis, and proliferation. We previously established subclones of GBM cells with distinct invasive phenotypes and identified annexin A2 (ANXA2) as an activator of angiogenesis and perivascular invasion. Here, we further explored the role of ANXA2 in regulating phenotypic transition in GBM. ... Read more >>

Acta Neuropathol Commun (Acta neuropathologica communications)
[2020, 8(1):42]

Cited: 0 times

View full text PDF listing >>



lncRNA and mRNA signature for prognosis prediction of glioblastoma.

Guohong Liu, Yunbao Pan, Yueying Li, Haibo Xu,

Aims: We aimed to find out potential novel biomarkers for prognosis of glioblastoma (GBM). Materials & methods: We downloaded mRNA and lncRNA expression profiles of 169 GBM and five normal samples from The Cancer Genome Atlas and 129 normal brain samples from genotype-tissue expression. We use R language to perform ... Read more >>

Future Oncol (Future oncology (London, England))
[2020, :]

Cited: 0 times

View full text PDF listing >>



Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials.

Li Lv, Jiangchao Huang, Haipeng Xi, Xiangyang Zhou,

BACKGROUND:Dendritic cell (DC)-based vaccination has been suggested to be promising for glioblastoma. However, the evidence in randomized controlled trials (RCTs) is inconsistent. We aimed to systematically evaluate the efficacy and safety of DC vaccine for glioblastoma via a meta-analysis of RCTs. METHODS:Related randomized controlled trials (RCTs) were identified via a ... Read more >>

Int. Immunopharmacol. (International immunopharmacology)
[2020, 83:106336]

Cited: 0 times

View full text PDF listing >>



Glioblastoma under siege of Therapeutics and Research: "Advancements and Future Targets".

Vishal Chavda, Vimal Patel, Dhananjay Yadav, Jigar Shah, Snehal Patel, Jun-O Jin,

Glioblastoma, most common primary brain tumor has been recognized as a one of the most lethal and fatal human tumors, which has a dismal prognosis with an average life duration not more than 15 months and end up with surgery and radiotherapy which ideally suggest a hope to escape an ... Read more >>

Curr. Drug Metab. (Current drug metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Growth inhibitory activity of bone morphogenetic protein 4 in human glioblastoma cell lines is heterogeneous and dependent on reduced SOX2 expression.

Erika Dalmo, Patrik Johansson, Mia Niklasson, Ida Gustavsson, Sven Nelander, Bengt Westermark,

Glioblastoma multiforme (GBM) continues to have a dismal prognosis. Even though detailed information on the genetic aberrations in cell signaling and cell cycle checkpoint control is available, no effective targeted treatment has been developed. Despite the advanced molecular defects, glioblastoma cells may have remnants of normal growth inhibitory pathways, such ... Read more >>

Mol. Cancer Res. (Molecular cancer research : MCR)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor.

Saumya S Gurbani, Brent D Weinberg, Eric Salgado, Alfredo Voloschin, Jose Enrique Velazquez Vega, Jeffrey J Olson, Hui-Kuo G Shu, Hyunsuk Shim,

AbstractSecondary glioblastoma is a rare brain tumor characterized by a mutation in isocitrate dehydrogenase, which is reported to lead to epigenetic modification. Patients with secondary glioblastoma experience poor survival and quality-of-life outcomes due to the disease’s aggressiveness and a lack of targeted therapies. In this report, a patient with a ... Read more >>

Oxf Med Case Reports (Oxford Medical Case Reports)
[2020, 2020(3):]

Cited: 0 times

View full text PDF listing >>



A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway.

Shan Zhang, Yunyang Lu, Hua Li, Yuqiang Ji, Fei Fang, Haifeng Tang, Pengcheng Qiu,

Glioblastoma is one of the most difficult cancers to treat with a 5-year overall survival rate less than 5%. Temozolomide (TMZ) is an effective drug for prolonging the overall survival time of patients, while drug-resistance is an important clinical problem at present. Pennogenin-3-α-L-rhamnopyranosyl-(1→4)-[α-Lrhamno-pyranosyl-(1→2)]- β-D-glucopyranoside (N45), a steroidal saponin, was isolated ... Read more >>

Biosci Trends (Bioscience trends)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor.

Saumya S Gurbani, Brent D Weinberg, Eric Salgado, Alfredo Voloschin, Jose Enrique Velazquez Vega, Jeffrey J Olson, Hui-Kuo G Shu, Hyunsuk Shim,

Secondary glioblastoma is a rare brain tumor characterized by a mutation in isocitrate dehydrogenase, which is reported to lead to epigenetic modification. Patients with secondary glioblastoma experience poor survival and quality-of-life outcomes due to the disease's aggressiveness and a lack of targeted therapies. In this report, a patient with a ... Read more >>

Oxf Med Case Reports (Oxford medical case reports)
[2020, 2020(3):omaa006]

Cited: 0 times

View full text PDF listing >>



LZTR1 inactivation promotes MAPK/ ERK pathway activation in glioblastoma by stabilizing oncoprotein RIT1

Yuqi Wang, Jianong Zhang, Pingzhao Zhang, Zhipeng Zhao, Qilin Huang, Dapeng Yun, Juxiang Chen, Hongyan Chen, Chenji Wang, Daru Lu,

ABSTRACT Large-scale sequencing studies on glioblastoma have identified numerous genetic alterations. Leucine-zipper-like transcription regulator 1 ( LZTR1 ) is inactivated by non-synonymous mutations and copy number losses, suggesting that it is a tumor suppressor in glioblastoma. However, how LZTR1 mutations contribute to glioblastoma pathogenesis remains poorly understood. Here, we revealed ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0237 s